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In Response:
We thank Dr. Zhang for his 
thoughtful comments on our arti-
cle, “Phase II Trial of Gefitinib in 
Combination with Bevacizumab as 
First-Line Therapy for Advanced Non–
Small Cell Lung Cancer with Activating 
EGFR Gene Mutations: The Okayama 
Lung Cancer Study Group Trial 1001.” 
He raised some important issues about 
bevacizumab (bev) and gefitinib combi-
nation therapy.
Dr. Zhang referred to recent arti-
cles investigating combination therapies 
containing bev in elderly patients1 and 
questioned its tolerability and benefit. 
Both of the articles he cited focus on bev 
in combination with cytotoxic agents, 
showing less efficacy and more toxicity 
in elderly patients. Although the data on 
bev in combination with cytotoxic agents 
for elderly patients are controversial to 
an extent, it seems to be less beneficial 
and more toxic. However, we should 
consider the combination of bev with 
molecular targeted agents such as erlo-
tinib or gefitinib separately because their 
magnitudes of efficacy and toxicologi-
cal profiles differ from cytotoxic agents. 
There is no evidence of higher toxicity 
in elderly patients treated with bev and 
erlotinib or gefitinib. Furthermore, even 
elderly patients with epidermal growth 
factor receptor (EGFR)-mutated lung 
cancers had greater benefit when treated 
with bev in combination with erlotinib.2 
We agree that elderly patients should 
be followed very carefully during treat-
ment, even when bev is combined with 
a molecular targeted agent such as gefi-
tinib or erlotinib, because of their slower 
metabolism, poorer performance status, 
and increased comorbidities, potentially 
leading to greater toxicity.
Regarding cost-effectiveness, 
we agree that economic evaluation is 
essential when developing a new cancer 
treatment as the cost of pharmacologi-
cal cancer therapy is increasing at an 
incredible pace. As Dr. Zhang men-
tioned, an incremental cost-effective-
ness ratio (ICER) per quality-adjusted 
life-year (QALY) gained is often used 
to evaluate cost efficacy and an ICER 
per QALY of less than a certain value 
(£20,000 in the United Kingdom and 
$50,000 in the United States) is gen-
erally considered as cost effective. 
However, calculating the ICER itself 
has potential problems3: difficulty in 
determining such a threshold based 
on evidence; uncertainty in measuring 
utility values; and a tendency to obtain 
a lower QALY in elderly or sicker 
patients with lower expectation of life. 
We should not only include a cost-effi-
cacy parameter in clinical trials but also 
need to have a broad discussion about 
how it should be evaluated.
Finally, we agree with Dr. 
Zhang’s suggestion that it is neces-
sary to identify predictive biomark-
ers of acquired resistance to bev and 
gefitinib. In addition, we need to know 
which mechanisms cause resistance 
to a combination of bev and gefitinib, 
those of bev resistance (angiogenic 
pathways other than the vascular epi-
dermal growth factor pathway4), those 
of gefitinib resistance (secondary 
EGFR T790M mutation, MET ampli-
fication, etc.5), or other yet undefined 
mechanisms. Given that gefitinib itself 
can inhibit EGFR-mutated lung can-
cers, it is unlikely that just bev-resistant 
mechanisms will induce resistance to a 
combination of bev and gefitinib. If bev 
and gefitinib resistance is caused by the 
same mechanisms as those of gefitinib 
resistance, it might be potentially ben-
eficial to continue bev in subsequent 
therapies because the tumors might not 
be resistant to bev itself.
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To the Editor:
Rare epidermal growth factor 
receptor (EGFR) mutations in non–
small-cell lung cancer have been fre-
quently reported in the last decade. A 
high incidence and large variety have 
been identified in several cohorts.1 
Notably, clinical characteristics and 
